Weill Cornell Medicine has received $4.2 million to study how the immune system in some people infected with HIV can keep the virus under control, which could lead to new therapies.
By repeatedly scanning the brains of a small group of patients for a year and a half, Weill Cornell Medicine researchers have identified a distinct pattern of neuronal interactions that appears to predispose some people to developing depression.
A multidisciplinary team aims to build a more inclusive AI shaped by global cultures and knowledge – one of three projects that make up Cornell’s new GlobalGrand Challenge: The Future.
A novel combination of surgery and embolization used to treat subdural hematomas, bleeding between the brain and its protective membrane due to trauma, reduces the risk of follow-up surgeries, according to researchers at Weill Cornell Medicine and University at Buffalo.
A new preclinical model using CRISPR has given Weill Cornell Medicine researchers and their colleagues a deeper insight into how prostate cancer spreads or metastasizes.
The findings could lead to new treatments targeting a particular protein to better manage inflammation in patients who don’t respond well to existing therapies.
A multi-institutional clinical trial led by Weill Cornell Medicine and NewYork-Presbyterian investigators showed that a newer technique for collecting prostate biopsy samples reduced the risk of infection compared with traditional biopsy approaches.
A new technology enables the control of specific brain circuits non-invasively with magnetic fields, according to a preclinical study from researchers at Weill Cornell Medicine, the Rockefeller University and the Icahn School of Medicine at Mount Sinai.
A new consortium co-led by Weill Cornell Medicine has been awarded a five-year, $31 million grant from the NIH’s National Institute of Allergy and Infectious Diseases to accelerate the development of better treatment regimens for tuberculosis.